The Eye Melanoma Market segment is logically segmented by treatment modality, disease stage, and end-user. By treatment modality, the market is divided into Radiation Therapy (Plaque Brachytherapy, Proton Beam), Surgical Interventions (Enucleation, Resection), and Drug Therapy (Immunotherapy, Targeted Therapy, Chemotherapy). The systemic drug therapy segment, despite being the newest, is the fastest-growing and highest-revenue segment due to the cost of novel biopharma agents used in metastatic disease.

Segmentation by disease stage separates the market into localized (primary) and metastatic. The primary stage drives demand for surgical and radiation equipment, while the metastatic stage drives the high-value systemic drug segment. End-user segmentation focuses on specialized ocular oncology centers, hospitals, and ambulatory surgical centers. The high cost and complexity of the treatments ensure that specialized oncology centers dominate the end-user segment. Understanding these segments is key for manufacturers to target R&D investment and sales efforts toward the highest-value segment—the systemic treatment of metastatic disease.